First Time Loading...

AcelRx Pharmaceuticals Inc
NASDAQ:ACRX

Watchlist Manager
AcelRx Pharmaceuticals Inc Logo
AcelRx Pharmaceuticals Inc
NASDAQ:ACRX
Watchlist
Price: 1.1277 USD 2.52% Market Closed
Updated: May 4, 2024
Section:
 

Wall Street
Price Targets

ACRX Price Targets Summary
AcelRx Pharmaceuticals Inc

Wall Street analysts forecast ACRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ACRX is 4.63 USD .

ACRX Lowest Forecast
Wall Street Target
Not Available
ACRX Average Forecast
Wall Street Target
4.63 USD
311% Upside
ACRX Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
4.63 USD
311% Upside
Highest
Price Target
Not Available
AcelRx Pharmaceuticals Inc Competitors:
Price Targets
033270
Korea United Pharm Inc
40% Upside
XERS
Xeris Biopharma Holdings Inc
163% Upside
J
300497
Jiangxi Fushine Pharmaceutical Co Ltd
148% Upside
019170
Shinpoong Pharmaceutical Co Ltd
59% Downside
033270
Korea United Pharm Inc
40% Upside
XERS
Xeris Biopharma Holdings Inc
163% Upside
J
300497
Jiangxi Fushine Pharmaceutical Co Ltd
148% Upside
019170
Shinpoong Pharmaceutical Co Ltd
59% Downside
H
600566
Hubei Jumpcan Pharmaceutical Co Ltd
30% Upside
GLAXO
GlaxoSmithKline Pharmaceuticals Ltd
2% Downside
234080
JW Life Science Corp
48% Upside
D
086450
Dongkook Pharmaceutical Co Ltd
47% Upside

Revenue
Forecast

Revenue Estimate
AcelRx Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for AcelRx Pharmaceuticals Inc's revenue is -13%. The projected CAGR for the next 2 years is -12%.

-13%
Past Growth
-12%
Estimated Growth
Estimates Accuracy
-28%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
AcelRx Pharmaceuticals Inc

Operating Income forecast
is not available for
AcelRx Pharmaceuticals Inc

Net Income
Forecast

Net Income Estimate
AcelRx Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
ACRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
ACRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ACRX stock valuation using valuation multiples.
Wall Street Estimates
ACRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ACRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ACRX's stock price target?
Price Target
4.63 USD

According to Wall Street analysts, the average 1-year price target for ACRX is 4.63 USD .

What is AcelRx Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
-12%

For the last 8 years the compound annual growth rate for AcelRx Pharmaceuticals Inc's revenue is -13%. The projected CAGR for the next 2 years is -12%.

ALPHA SPREAD
Join more than 133,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.